NO20042697L - Fremgangsmater for behandling av kreft ved anvendelse av en kombinasjon av en tumoravledet dendrittcelleinhiberende faktor-antagonist og en Toll-lignende reseptorantagonist - Google Patents

Fremgangsmater for behandling av kreft ved anvendelse av en kombinasjon av en tumoravledet dendrittcelleinhiberende faktor-antagonist og en Toll-lignende reseptorantagonist

Info

Publication number
NO20042697L
NO20042697L NO20042697A NO20042697A NO20042697L NO 20042697 L NO20042697 L NO 20042697L NO 20042697 A NO20042697 A NO 20042697A NO 20042697 A NO20042697 A NO 20042697A NO 20042697 L NO20042697 L NO 20042697L
Authority
NO
Norway
Prior art keywords
antagonist
toll
tumor
methods
combination
Prior art date
Application number
NO20042697A
Other languages
English (en)
Norwegian (no)
Inventor
Alain P Vicari
Christophe Caux
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20042697L publication Critical patent/NO20042697L/no

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
NO20042697A 2001-11-27 2004-06-25 Fremgangsmater for behandling av kreft ved anvendelse av en kombinasjon av en tumoravledet dendrittcelleinhiberende faktor-antagonist og en Toll-lignende reseptorantagonist NO20042697L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33343401P 2001-11-27 2001-11-27
PCT/US2002/038098 WO2003045431A2 (en) 2001-11-27 2002-11-26 Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist

Publications (1)

Publication Number Publication Date
NO20042697L true NO20042697L (no) 2004-06-25

Family

ID=23302758

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042697A NO20042697L (no) 2001-11-27 2004-06-25 Fremgangsmater for behandling av kreft ved anvendelse av en kombinasjon av en tumoravledet dendrittcelleinhiberende faktor-antagonist og en Toll-lignende reseptorantagonist

Country Status (14)

Country Link
US (2) US20030138413A1 (enExample)
EP (1) EP1450858A2 (enExample)
JP (3) JP2006502080A (enExample)
CN (1) CN1617742B (enExample)
AU (1) AU2002359516B2 (enExample)
BR (1) BR0214457A (enExample)
CA (1) CA2468320A1 (enExample)
HU (1) HUP0500999A2 (enExample)
MX (1) MXPA04004998A (enExample)
NO (1) NO20042697L (enExample)
NZ (1) NZ565420A (enExample)
TW (1) TW200303759A (enExample)
WO (1) WO2003045431A2 (enExample)
ZA (1) ZA200404113B (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DK1077722T3 (da) 1998-05-22 2006-11-27 Ottawa Health Research Inst Fremgangsmåder og produkter til induktion af mukosaimmunitet
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
WO2001051500A1 (en) 2000-01-14 2001-07-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
US20040175355A1 (en) * 2001-04-18 2004-09-09 The Regents Of The University Of California Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US7354909B2 (en) * 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
US7387271B2 (en) * 2002-12-30 2008-06-17 3M Innovative Properties Company Immunostimulatory combinations
US8795672B2 (en) * 2003-02-14 2014-08-05 University Of Southern California Compositions and methods for cancer immunotherapy
CN101675993A (zh) 2003-03-26 2010-03-24 赛托斯生物技术公司 Melan-a肽类似物-病毒样颗粒偶联物
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
WO2005014110A1 (en) * 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes
ES2689328T3 (es) 2004-01-07 2018-11-13 Novartis Vaccines And Diagnostics, Inc. Anticuerpo monoclonal M-CSF-específico y usos del mismo
JP2007526253A (ja) * 2004-02-19 2007-09-13 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激性ウイルスｒｎａオリゴヌクレオチド
JP2008522951A (ja) * 2004-07-19 2008-07-03 ベイラー・カレツジ・オブ・メデイシン サイトカインシグナル伝達調節物質の調節および免疫療法のための応用
WO2006014653A1 (en) * 2004-07-20 2006-02-09 Schering Corporation Induction of apoptosis in toll-like receptor expressing tumor cells
WO2007050095A2 (en) 2004-11-19 2007-05-03 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
JPWO2006077724A1 (ja) * 2004-12-28 2008-06-19 株式会社イミュノフロンティア がんワクチン製剤
EP1712241A1 (en) * 2005-04-15 2006-10-18 Centre National De La Recherche Scientifique (Cnrs) Composition for treating cancer adapted for intra-tumoral administration and uses thereof
US20100143899A1 (en) * 2005-05-17 2010-06-10 University Of Vermont And State Agricultural College Methods and products for diagnosing cancer
CN101501055B (zh) * 2005-06-23 2016-05-11 贝勒医学院 负性免疫调节因子的调节和免疫疗法应用
EP1906989A4 (en) * 2005-07-11 2009-08-19 Cbio Ltd IMMUNOMODULATION INDUCED BY CHAPERONIN 10
NZ569086A (en) * 2005-12-01 2011-07-29 Trinity College Dublin Compositions comprising a Toll-like receptor (TLR) agonist and an immune modulator for treating Th1-mediated conditions, such as cancer and infectious diseases
AU2006325225B2 (en) 2005-12-14 2013-07-04 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
SI2032592T1 (sl) 2006-06-12 2013-10-30 Cytos Biotechnology Ag Postopki za pakiranje oligonukleotidov v virusu-podobne delce RNA bakteriofagov
DE102006035618A1 (de) * 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
US20080124366A1 (en) * 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
EP2079305A4 (en) * 2006-12-12 2010-01-27 Idera Pharmaceuticals Inc SYNTHETIC AGONISTS OF TLR9
WO2008134020A1 (en) * 2007-04-26 2008-11-06 University Of Vermont And State Agricultural College Ccl18 and ccl3 methods and compositions for detecting and treating cancer
EP2222344A4 (en) * 2007-11-30 2012-11-07 Baylor College Medicine VACCINATE COMPOSITIONS WITH DENDRITIC CELLS AND THEIR USE
JP2012516352A (ja) * 2009-01-30 2012-07-19 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９の合成アゴニスト
JP5950824B2 (ja) 2009-12-07 2016-07-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗腫瘍抗体療法を増強するための方法
WO2011097384A2 (en) * 2010-02-04 2011-08-11 Board Of Regents, The University Of Texas System Tumor targeted delivery of immunomodulators by nanoplymers
US20130108661A1 (en) 2010-02-05 2013-05-02 Mount Sinai School Of Medicine Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells
US9890202B2 (en) 2010-07-19 2018-02-13 Yeda Research And Development Co. Ltd. Peptides based on the transmembrane domain of a toll-like receptor (TLR) for treatment of TLR-mediated diseases
KR20130108295A (ko) * 2010-08-13 2013-10-02 베일러 리서치 인스티튜트 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
EP2858722B8 (en) * 2012-06-08 2018-02-21 Aduro BioTech, Inc. Compostions and methods for cancer immunotherapy
RU2678083C2 (ru) * 2012-06-27 2019-01-23 Кенитиро Хасуми Терапия и способ внутриопухолевого введения цитотоксического т-лимфоцита и/или nkt-клетки с антителом против tnf и/или антителом против il-10
CN104603156B (zh) 2012-09-05 2016-10-26 中外制药株式会社 引入有氨基酸和甾基的透明质酸衍生物
CN103768604B (zh) * 2012-10-24 2016-03-30 北京圣沃德生物科技有限公司 治疗性肿瘤疫苗
SG11201502796RA (en) 2012-12-13 2015-05-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
CN103013915B (zh) * 2013-01-09 2014-05-28 高岱清 一种高活性负载抗原的树突状细胞的制备方法
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
CN105377867B (zh) 2013-05-03 2019-11-12 加利福尼亚大学董事会 I型干扰素的环状二核苷酸诱导
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
EP2996472B1 (en) 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
PT3291821T (pt) * 2015-05-07 2026-03-18 Baylor College Medicine Imunoterapêutica com células dendríticas
EP3292152A1 (en) 2015-05-07 2018-03-14 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
MX2017015311A (es) * 2015-05-29 2018-06-19 Merck Sharp & Dohme Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer.
KR102779525B1 (ko) * 2015-05-29 2025-03-12 다이나박스 테크놀로지 코퍼레이션 폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여
US20200079860A1 (en) * 2015-08-06 2020-03-12 Memorial Sloan Kettering Cancer Center Methods and compositions for tumor therapy
TW201716084A (zh) * 2015-08-06 2017-05-16 葛蘭素史克智慧財產發展有限公司 組合物及其用途與治療
CR20180229A (es) 2015-10-29 2018-08-24 Novartis Ag Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
WO2017096179A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
WO2017192470A1 (en) * 2016-05-03 2017-11-09 Merck Sharp & Dohme Corp. Combination therapy of anti-il-10 antibody and compositions comprising lipid nanoparticles and tlr9 agonist cpg oligonucleotides
WO2017214706A1 (en) * 2016-06-15 2017-12-21 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018060513A1 (en) 2016-09-30 2018-04-05 Galderma Research & Development Methods and compositions for treating precancerous lesions or cancer comprising tlr/tlr or tlr/clr agonists
WO2018060514A1 (en) 2016-09-30 2018-04-05 Galderma Research & Development Methods and compositions combining at least one pattern recognition receptor (prr) agonist with an anti-il10 receptor antibody
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
IL268744B2 (en) * 2017-02-17 2024-08-01 Aivita Biomedical Inc Methods for increasing the immunogenicity of tumors and preparations for autologous immunotherapeutic products against cancer using tumor cells and adapted dendritic cells
EP3635410A4 (en) * 2017-06-04 2021-03-10 Rappaport Family Institute for Research in the Medical Sciences PROCEDURE FOR PREDICTING PERSONALIZED RESPONSE TO CANCER TREATMENT USING IMMUNE CHECKPOINT INHIBITORS AND KITS
WO2019246111A1 (en) * 2018-06-19 2019-12-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Oncolytic virus or antigen presenting cell mediated cancer therapy using type i interferon and cd40-ligand
CN113005090A (zh) * 2019-12-20 2021-06-22 上海细胞治疗集团有限公司 共表达趋化因子和共刺激分子的dc细胞及其应用
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
US20230210968A1 (en) * 2020-06-11 2023-07-06 Massachusetts Institute Of Technology Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7397887A (en) * 1986-05-09 1987-12-01 Sloan-Kettering Institute For Cancer Research Lipopolysaccharide and natural factor compositions for anti-tumor therapy and method of treatment
JPH08504766A (ja) * 1992-12-14 1996-05-21 スタート テクノロジー パートナーシップ ドーパミン作動性神経系の病態の診断および治療に関するドーパミン受容体ｍＲＮＡに対してアンチセンスのオリゴヌクレオチドの投与
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
AU713040B2 (en) * 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6071535A (en) * 1996-01-31 2000-06-06 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
WO1998016247A1 (en) * 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US7390619B1 (en) * 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US6218371B1 (en) * 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
DK1187629T3 (da) * 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
EP1261366A4 (en) * 2000-02-24 2003-06-18 Univ Leland Stanford Junior ADJUVANT TREATMENT BY IN VIVO ACTIVATION OF DENDRITIC CELLS
EP1283722A1 (en) * 2000-03-31 2003-02-19 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma

Also Published As

Publication number Publication date
ZA200404113B (en) 2006-03-29
JP2006131638A (ja) 2006-05-25
AU2002359516B2 (en) 2006-02-02
NZ565420A (en) 2009-09-25
US20030138413A1 (en) 2003-07-24
US20090087440A1 (en) 2009-04-02
CA2468320A1 (en) 2003-06-05
CN1617742B (zh) 2010-10-27
BR0214457A (pt) 2006-11-21
CN1617742A (zh) 2005-05-18
TW200303759A (en) 2003-09-16
MXPA04004998A (es) 2005-04-08
HUP0500999A2 (en) 2007-11-28
WO2003045431A3 (en) 2004-01-22
EP1450858A2 (en) 2004-09-01
JP2006502080A (ja) 2006-01-19
WO2003045431A2 (en) 2003-06-05
AU2002359516A1 (en) 2003-06-10
JP2010053140A (ja) 2010-03-11

Similar Documents

Publication Publication Date Title
ZA200404113B (en) Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist
NO20033995D0 (no) Fremgangsmåte ved frakturering av en underjordisk formasjon
IL166625A0 (en) Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
DK3342411T3 (da) Rapamycinderivat til behandling af pancreascancer
DK1360287T3 (da) Fremgangsmåder til modifikation af eukaryotiske celler
NO20031489D0 (no) Fremgangsmåte og anordning ved trekkbar broplugg
PL363339A1 (en) Method of checking ballast profile
PL371492A1 (en) Quinolinone derivatives for treating cell proliferation related disorders
NO20033684L (no) Behandling av refrakt¶re tumorer ved anvendelse av epotilonderivater
NO20032966D0 (no) Fremgangsmåte og anordning ved utboring av sementplugger
NO20033429L (no) Fremgangsmåter for behandling av inflamatoriske og immunsykdommer ved anvendelse av inhibitorer av I-kappa-B kinase (IKK)
PL359556A1 (en) Method - use of cox-2 inhibitors for preventing immunodeficiency
EP1390052A4 (en) INHIBITION OF JUN KINASE
PL1781321T3 (pl) Sposób leczenia raka zawierający antagonistę VEGF-B
AU2002308522A8 (en) Methods for inhibiting tumor cell proliferation
AU2003231084A8 (en) Identification of biomarkers for detecting prostate cancer
EP1569516A4 (en) METHOD OF INHIBITING CANCER AND TARGET EDUCATION
GB0201504D0 (en) Method of payment
IS7438A (is) Lyfjablanda úr PDE4 eða PDE3/4 tálma og histamínviðtakamótlyfi
EP1534317A4 (en) N-TERMINAL TRONQUEE GALECTIN-3 AND ANTIBODIES FOR THE TREATMENT OF CANCER
GB0101686D0 (en) Cyclin dependent kinase inhibitors
GB0124272D0 (en) Method of delivering money
NO20006537D0 (no) Fremgangsmåte og anordning ved bunndetektor
EP1425393A4 (en) SEARCH FOR CDC7 INHIBITORS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application